Evelyn M. Horn

Sort by:

Sitaxsentan therapy for pulmonary arterial hypertension.

Robyn J. Barst, David Langleben, +11 authors Lyn R. Frumkin
American journal of respiratory and critical care…
2004

Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions of endothelin-B… (More)

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.

Marc Humbert, Robyn J. Barst, +7 authors Gérald Simonneau
The European respiratory journal
2004

The efficacy and safety of combining bosentan, an orally active dual endothelin receptor antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of pulmonary arterial… (More)

New predictors of outcome in idiopathic pulmonary arterial hypertension.

Steven M. Kawut, Evelyn M. Horn, +6 authors Robyn J. Barst
The American journal of cardiology
2005

Idiopathic pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis. New therapies have improved the outcome of this condition; accordingly, the factors that determine outcome… (More)

World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the…

James Chen-Tson Fang, Teresa Demarco, +9 authors Raymond L. Benza
The Journal of heart and lung transplantation…
2012

Pulmonary hypertension associated with left heart disease is the most common form of pulmonary hypertension encountered in clinical practice today. Although frequently a target of therapy, its… (More)

Clinical risk factors for portopulmonary hypertension.

Steven M. Kawut, Michael J. Krowka, +9 authors Michael Brooks Fallon
Hepatology
2008

UNLABELLED Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the predictors and biologic mechanism for the development of this complication are unknown. We… (More)

Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.

Steven M. Kawut, E Bagiella, +11 authors Reda E. Girgis
Circulation
2011

BACKGROUND Pulmonary arterial hypertension (PAH) is a progressive disease that causes exercise limitation, heart failure, and death. We aimed to determine the safety and efficacy of aspirin and… (More)

Characteristics of Hospitalizations for Heart Failure with Preserved Ejection Fraction.

Parag Goyal, Zaid I. Almarzooq, +9 authors Luke K. Kim
The American journal of medicine
2016

BACKGROUND Hospitalizations for heart failure with preserved ejection fraction (HFpEF) are increasing. There are limited data examining national trends in patients hospitalized with HFpEF. METHODS… (More)

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

Evelyn M. Horn, Robyn J. Barst, Michael Poon
Chest
2000

As reported by Robbins et al (January 2000),1 although IV epoprostenol therapy improves symptoms, exercise tolerance, and hemodynamics in patients with pulmonary hypertension associated with systemic… (More)

Plasma serotonin levels are normal in pulmonary arterial hypertension.

David J. Lederer, Evelyn M. Horn, +4 authors Steven M. Kawut
Pulmonary pharmacology & therapeutics
2008

Serotonin (5-HT) has been implicated in the pathogenesis of pulmonary arterial hypertension (PAH). We hypothesized that plasma 5-HT would be elevated in PAH related to associated conditions. We… (More)

Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Kari E. Roberts, Michael Brooks Fallon, +13 authors Steven M. Kawut
American journal of respiratory and critical care…
2009

RATIONALE Portopulmonary hypertension (PPHTN) occurs in 6% of liver transplant candidates. The pathogenesis of this complication of portal hypertension is poorly understood. OBJECTIVES To identify… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences